NewsBite

Hedge funds

This Month

Trillions of dollars were wiped from Wall Street over just two days last week, with traders expecting the turmoil to continue.

ASX braces for capitulation after $9trn wiped from Wall Street

The country’s major asset managers and hedge funds will suffer historically large losses when the market opens, compounding a difficult year with poor returns.

Thursday was the worst day of performance for US-based long/short equity funds since it began tracking the data in 2016.

Hedge funds hit with steepest margin calls since COVID-19 crisis

Wall Street banks have asked their fund clients to stump up more money as security for their loans because the value of their holdings had tumbled.

Traders on the floor of the New York Stock Exchange on Friday. Super funds appeared ill prepared for the double whammy of a cyberattack and a global market meltdown.

With global markets in turmoil, big super faces an epic stress test

The major funds will get a chance to prove they can handle the turbulence. But the financial system’s vulnerabilities have shifted from banks to pensions.

The ASX finished flat on Thursday despite hitting a two-month high early in the session

RBC shops at Morgan Stanley for hedge fund sales trader

Head of equities Karen Jorritsma told staff in an internal memo on Thursday the investment bank had lured across Sutton from Morgan Stanley.

Regal co-founder Phil King says he got Opthea wrong.

Phil King’s Regal writes Opthea to zero and backs off risky bets

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ensure it does not occur again”.

Advertisement

March

Biotech investing is not for the unwary.

Opthea in active talks with funders after second trial fails

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye disease treatment had failed.

Michael Hintze at his office in London “You can’t out-trade a machine, but you can out-think it,” he says.

Hedge fund veteran Michael Hintze on the rise of machines, and returns

It has been a year since the billionaire investor sold his storied London fund. Now he’s back with a new fund in the midst of a rapidly shifting market.

Minotaur’s Thomas Rice believes markets are yet to recognise how European defence company earnings will evolve over the next decade.

This fundie shorted WiseTech and Tesla while loading up on war stocks

Betting against Richard White and Elon Musk while going long on defence companies are among this year’s hottest trades. Minotaur’s Tom Rice did it all.

The clinical trial result from hell has biotech investors on edge

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea. Now they risk being wiped out.

Phil King is the co-founder of Regal Partners, which has been a major investor in Opthea.

Regal’s listed funds slash value of biotech Opthea by two-thirds

The hedge fund run by veteran stockpicker Phil King has told investors that the eye treatment play is worth 20¢ per share. It is the company’s largest investor.

.

Rio warns ASX-listed shares could slump 11pc if unification proceeds

Two influential governance advisers have backed a hedge fund-instigated vote that would force the miner to assess collapsing its dual-company structure.

Crispin Odey, the founder of OAM.

Hedge fund boss Odey banned from working for ‘lack of integrity’

The UK regulator’s decision could mark the closing chapter in the stunning downfall of one of Britain’s most high-profile investment managers.

Regal’s Phil King will be holding thumbs ahead of Opthea’s clinical trial results.

It’s Phil King’s Regal against the shorts at biotech play Opthea

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial clinical trial, shorts are rising.

Private credit wants to work alongisde the banking sector.

Private equity is taking a public market beating

Gyrations on listed equities have delivered a double blow for PE. But one billionaire investor sees change coming.

Regal chief executive Brendan O’Connor sold more than $3 million in the company’s shares last week.

Regal chief executive Brendan O’Connor dumps $3.4m in fund’s shares

The sale represented about 10 per cent of his holdings in the funds management business founded by stockpicker Phil King and came despite a share slump.

Advertisement
Citadel’s Ken Griffin is telling his team to go on the “offence”.

Wall Street’s hedge fund giants hit by Trump’s trade war

Citadel and Millennium are among the biggest multi-strategy funds in New York that are being forced to unwind crowded trades at a ferocious clip.

Star Entertainment’s future is back up in the air, following an offer by US casinos owner Bally’s Corporation.

How Star’s ‘buyer of last resort’ entered its orbit at a meeting in New York

Star Entertainment looked everywhere for funds in recent months, just not the place it would end up attracting a bid. Why not?

Ray Dalio, billionaire and founder of Bridgewater Associates.

Hedge fund giant Bridgewater bets against Australian stocks and bonds

Founded by Ray Dalio, the American investment giant will gain if the sharemarket falls and if long-term interest rates increase, new disclosures show.

Australian-born Russell Clark bet against the market before calling it quits in 2021.

An Australian perma bear ends retirement as markets turn upside down

Russell Clark was one of the world’s most bearish, and successful, hedge fund operators. After four years, he sees plenty of pain and is back for a second act.

The Rio Tinto annual meeting in Brisbane last year. It had baulked at allowing shareholders to vote on the first step towards delisting from the London Stock Exchange.

Rio’s Australian shareholders to vote on London listing question

The mining giant faces a push from activist investors to reassess its dual-listed structure and leave the London Stock Exchange like major rival BHP did.

Original URL: https://www.afr.com/topic/hedge-funds-huk